Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
203.04
+5.96 (3.02%)
At close: Feb 6, 2026, 4:00 PM EST
202.00
-1.04 (-0.51%)
After-hours: Feb 6, 2026, 5:05 PM EST
Natera Revenue
Natera had revenue of $592.18M in the quarter ending September 30, 2025, with 34.66% growth. This brings the company's revenue in the last twelve months to $2.12B, up 38.17% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$2.12B
Revenue Growth
+38.17%
P/S Ratio
12.57
Revenue / Employee
$477,374
Employees
4,434
Market Cap
28.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 15.90B |
| Labcorp Holdings | 13.77B |
| Quest Diagnostics | 10.85B |
| Agilent Technologies | 6.95B |
| IDEXX Laboratories | 4.30B |
| Illumina | 4.29B |
| Mettler-Toledo International | 3.94B |
| Waters | 3.11B |
NTRA News
- 11 hours ago - Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes - Business Wire
- 3 days ago - Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards - Seeking Alpha
- 4 days ago - Natera Submits Signatera™ CDx PMA to FDA - Business Wire
- 8 days ago - Alger Small Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 9 days ago - Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation - Business Wire
- 11 days ago - Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care - Business Wire
- 11 days ago - Alger Small Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha
- 15 days ago - Alger Mid Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha